Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$160.85 USD

160.85
485,338

-0.78 (-0.48%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $160.88 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 249)

Industry: Medical - Instruments

Zacks News

Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.

Masimo (MASI) Q4 Earnings and Revenues Surpass Estimates

Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Stock Jumps 6%: Will It Continue to Soar?

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues

Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.

Here's Why You Should Retain Masimo (MASI) Stock For Now

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid

Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.

Here's Why You Should Retain Masimo (MASI) Stock For Now

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.

Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable

Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.

Masimo (MASI) Down 1.2% Since Last Earnings Report: Can It Rebound?

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings

The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.

Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.

Masimo (MASI) Beats Q3 Earnings and Revenue Estimates

Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 3.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Earnings Expected to Grow: Should You Buy?

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study

Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.

Here's Why You Should Retain Masimo (MASI) Stock For Now

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

Debanjana Dey headshot

Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on

Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.

Masimo (MASI) Launches SuperSensor, Boosts Product Profile

Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

Masimo (MASI) Strengthens Global Footprint With New Launch

Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.

Masimo (MASI) Up 6% Since Last Earnings Report: Can It Continue?

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Masimo (MASI) Stock For Now

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.